We are very excited to share the news of this important milestone, from our colleagues at Galapagos. We look forward to this being the first of many steps in the journey to enhancing #celltherapy #patientaccessibility through #decentralizedmanufacturing.
Press release: glpg.com/press-releases… | Galapagos announces FDA clearance of Investigational New Drug (IND) application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphomaView quoted post on X
#PioneeringForPatients